Navigation Links
Beckman Coulter to Acquire Siemens Healthcare Diagnostics' Clinical Microbiology Business

BREA, Calif., July 16, 2014 /PRNewswire/ -- Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announced today that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics.

The Siemens clinical microbiology business is an established leader in microbial identification and antibiotic sensitivity testing (ID/AST). The business operates with an installed base of over 6,000 instruments globally. The microbiology product line includes the MicroScan® Instruments and MicroScan® panels/consumables, along with data management solutions. The MicroScan systems are recognized in their industry for their high accuracy and superior detection of emerging resistance.

Beckman Coulter Diagnostics President Arnd Kaldowski said, "The clinical microbiology business will be an excellent complement to Beckman Coulter's Diagnostics business with a strong reputation and market position. Adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care. The acquisition expands our product portfolio with differentiated analytical systems and menu that elevate our clinical capabilities for customers, while driving continued growth."

The transaction is expected to close in Q1 2015. The agreement is subject to applicable regulatory approvals and other customary closing conditions.

About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Based in Brea, Calif., Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For more than 75 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes – offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation and information systems. Beckman Coulter is, and always has been, singularly devoted to moving science, innovation and the lab forward. For more information, visit

Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of the clinical microbiology business of Siemens Healthcare Diagnostics, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined company and any other statements about managements' future expectations, beliefs, goals, plans or prospects, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: general economic conditions and conditions affecting the industries in which the clinical microbiology business operates; the uncertainty of regulatory approvals; the parties' ability to satisfy the closing conditions and consummate the transaction; Beckman Coulter's ability to successfully integrate the clinical microbiology business' operations and employees with its existing business; and the ability to realize anticipated growth, synergies and cost savings.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher Corporation's SEC filings, including its 2013 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2014. These forward-looking statements speak only as of the date of this release and neither Beckman Coulter nor Danaher assumes any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Beckman Coulter and the stylized logo are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.Contacts:

Mary LuthyBeckman Coulter Company CommunicationsPhone: 714-961-6364Email: mluthy@beckman.comLaura BrightBeckman Coulter Diagnostics Public Relations Phone: 714-961-3909 Email: Logo -

SOURCE Beckman Coulter
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Atonomics Achieves Significant Milestone Related to Performance Data for Troponin I Assay Triggering Scheduled Payments From Beckman Coulter
2. Beckman Coulter Receives FDA Clearance of AccuTnI+3 Troponin I Assay on UniCel DxI Immunoassay Systems
3. Mindray Announced a Settlement Agreement with Beckman Coulter Inc
4. Apex BioStrategists Advises On Flow Cytometry Sale To Coulter
5. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
6. Watson to Acquire Actavis Group for EUR4.25 Billion
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
9. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
10. Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash
11. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
Post Your Comments:
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... 1, 2015 Building on its 25-year ... Johnson (NYSE: JNJ ) today announced four ... to significantly reduce the burden of HIV incidence, ... percent of new HIV infections among adolescents in ... Day, these new initiatives include collaborations with the ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
Breaking Medicine Technology:
(Date:12/1/2015)... N.C. (PRWEB) , ... December 01, 2015 , ... The ... to drive awareness and funds for Multiple System Atrophy (MSA) research, timed today to ... Atrophy takes many things from patients including their ability to work and be productive, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Royal River ... a new study that found post-menopausal women who took the nutritional supplement creatine, along ... women who trained but did not take creatine. , The report is part of ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville has ... the only hospital in the region providing what is known as the world’s ... patients were revealed recently at a medical conference and published in The New ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):